|
EQS-Ad-hoc: M1 Kliniken AG / Key word(s): Investment/Miscellaneous
M1 Kliniken AG: HAEMATO AG is reviewing an offer for the sale of its trading segment
01-Apr-2025 / 17:13 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.
M1 Kliniken AG: HAEMATO AG is reviewing an offer for the sale of its trading segment
HAEMATO AG, which is majority-owned by M1 Kliniken AG, has received a so-called Conditional Binding Offer (CBO) for the acquisition of its trading segment, the wholly-owned subsidiary HAEMATO PHARM GmbH. The Executive Board and Supervisory Board of HAEMATO AG are currently carefully reviewing the offer.
A possible sale of the trade segment would pave the way for a clear strategic focus of M1 Kliniken AG on the fast-growing beauty business.
The company will provide further information in due course.
Contact:
Attila Strauss, Management Board
Corporate Communications
E-Mail: ir@m1-kliniken.de
End of Inside Information
01-Apr-2025 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com
|
| Language: |
English |
| Company: |
M1 Kliniken AG |
|
Grünauer Straße 5 |
|
12557 Berlin |
|
Germany |
| Phone: |
+49 (0)30 347 47 44 14 |
| Fax: |
+49 (0)30 347 47 44 17 |
| E-mail: |
ir@m1-kliniken.de |
| Internet: |
https://www.m1-kliniken.de |
| ISIN: |
DE000A0STSQ8 |
| WKN: |
A0STSQ |
| Listed: |
Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Basic Board), Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: |
2110090 |
| |
| End of Announcement |
EQS News Service |
2110090 01-Apr-2025 CET/CEST
